MGMT and glioblastoma: The work by [61] shows that GBM patients harboring methylated MGMT promoters had a longer OS compared to unmethylated MGMT, suggesting a positive predictive value of MGMT methylation status in clinical response to TMZ; moreover, MGMT promoter methylation has been found to be associated with better OS and PFS in IDH mutant GBM patients [61,62].